Maria Stephanie Jardeleza, MD
Ophthalmology · Raleigh, NCNPI 1518125509
Payments from drug & device makers
Across 86 payments — averaging $172.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$12K
- Alcon$635
- Regeneron$635
- Genentech USA, Inc.$418
- AbbVie$347
- Astellas Pharma US Inc$153
- plus $344 from 7 others
What the payments were for
- Speaking & faculty fees$10,10568%
- Travel & lodging$1,0977%
- Food & beverage$3,63324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 30 | $12,304 |
| Alcon | 8 | $635 |
| Regeneron | 7 | $635 |
| Genentech USA, Inc. | 10 | $418 |
| AbbVie(2 entities) | 15 | $347 |
| Astellas Pharma US Inc | 2 | $153 |
| Novartis | 3 | $134 |
| Mallinckrodt Hospital Products Inc. | 4 | $73 |
| Aerie Pharmaceuticals, Inc. | 3 | $47 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Harrow Eye, LLC | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $24 |
| Genentech, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,835 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 82 | $4,449 |
| Ketorolac Tromethamine | 48 | $1,451 |
| Dorzolamide Hcl | 36 | $604 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 44 | $489 |
| Timolol Maleate | 25 | $221 |
| Tobramycin | 46 | $212 |
| ErythromycinErythromycin Base | 12 | $119 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Raleigh
- Preeya GuptaRaleigh$2M
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
- Rajiv ShahWinston Salem$1.3M
- Patrick KeltyHickory$1.1M
- Julie WoodwardDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.